Merck

Last updated January 31, 2026

124

Innovation Areas

5,362

Inventors

Collaborations

Anti-nucleating agent nanosuspension deposition: MerckRecent Research Landscape

Poor drug solubility leads to low bioavailability and wasted active ingredients, which is mitigated by stabilizing amorphous states through thin-film evaporation and anti-nucleating agents. This control over crystallization kinetics ensures consistent therapeutic delivery and shelf-life stability.

What technical problems is Merck addressing in Anti-nucleating agent nanosuspension deposition?

Poor aqueous drug solubility

(10)evidences

Low aqueous solubility of active pharmaceutical ingredients limits bioavailability and therapeutic efficacy. Overcoming this bottleneck ensures consistent drug absorption and reduces required dosage levels.

Poor aqueous drug solubility

(8)evidences

Inadequate dissolution and absorption of solid oral dosage forms in the digestive tract. Overcoming this limitation ensures therapeutic efficacy and consistent systemic delivery.